Purpose The efflux transporter breast cancer resistance protein (BCRP/ABCG2) plays an important role in excretion of anionic drugs and metabolites including glucuronides in humans. Methods In this article, our recently published cell model (i.e., HeLa cells over-expressing UGT1A9 (HeLa1A9)) is used to determine the kinetic parameters of BCRP-mediated transport of glucuronides. Results After incubation of the aglycone with the cells, a steady-state (i.e., zero-order or near zero-order) excretion of its glucuronide is rapidly achieved and then maintained. Kinetic profiling with different (intracellular) glucuronide concentrations and their corresponding excretion rates is enabled by varying the concentration of the aglycone, which allows for the determination of kinetic parameters responsible for BCRP-mediated efflux of glucuronides. This approach was validated theoretically using a cellular pharmacokinetic model incorporating various enzymatic and transporter-mediated kinetic processes. It was also validated experimentally in that kinetic parameters of efflux of glucuronides of 6-hydroxyflavone and 4-methylumberiferone in the HeLa1A9 cell model were shown to be consistent with those derived with BCRP-overexpressing membrane vesicles. Conclusion This study provides a new strategy for rapidly evaluating the kinetics of glucuronide efflux by BCRP.
INTRODUCTION
The human breast cancer resistance protein (BCRP/ ABCG2) is a member of the G subfamily of the large ATP-binding cassette (ABC) transporter superfamily. It is initially known as an efflux pump which renders cancer cells resistant to multiple chemotherapeutic agents such as methotrexate, mitoxantrone, topotecan, SN-38, imatinib and gefitinib (1) . In contrast to P-glycoprotein (P-gp) that possesses 12 transmembrane helices (TMs), BCRP is a half transporter with only six TMs. Therefore, two BCRP monomers in a dimeric form are required for transporter functionality (1) . In addition, the domain arrangement of BCRP is different from that of P-gp, following a unique "NBDlinker-TMD" pattern (i.e., the nucleotide binding domain (NBD) is located at the N-terminus of the polypeptide chain followed by a linker region and transmembrane domain (TMD)) (2) . Nevertheless, the overall experimentally determined topology structure of BCRP is similar to that of mouse P-gp, whose X-ray structure is known (3) .
The list of BCRP substrates has been rapidly expanding since its discovery. Aside from chemotherapeutic agents, BCRP substrates include a variety of non-chemotherapy drugs (e.g., glyburide and nitrofurantoin) and chemicals (e.g., hoechst33342) (2) . Of note is that most of the BCRP substrates are structurally unrelated. At present, what determines the substrate specificity of BCRP remains elusive. There is only one structure-activity relationship study for BCRP substrates (i.e., SN-38 and its analogs). This study suggests that camptothecin analogues with high polarity are good substrates for BCRP (4) . BCRP is located on the apical membrane of the epithelium of the small intestine and colon, and in the liver canalicular membrane, and its important role in drug/metabolites disposition is now widely recognized. For example, BCRP appears to (negatively) regulate the uptake (availability) of orally administered drugs (e.g., sulfasalazine (5) and irinotecan (6)), and to limit the penetration of topotecan into the central nervous system (7) . In recent years, numerous studies have shown that BCRP is involved in intestinal and/or biliary excretion of glucuronides of a diverse group of compounds including harmol (8) , acetaminophen (9,10) and dietary flavonoids (11) .
Glucuronidation is a significant metabolic pathway that facilitates efficient elimination and detoxification of numerous endo-(e.g., bilirubin and estradiol) and xenobiotics (e.g., SN-38 and indinavir) (12) . The involvement of efflux transporters such as BCRP in cellular glucuronide production is necessitated by the fact that glucuronide is too polar to passively diffuse out of cells. Therefore, in addition to UDPglucuronosyltransferases (UGTs) that catalyze glucuronidation reaction (i.e., glucuronide formation), efflux transporter is another element that enables glucuronide clearance. Impaired BCRP activity could result in reduced (intestinal/hepatic) glucuronide clearance and elevated glucuronide accumulation in systemic circulation (9, 11) . Moreover, modulation of glucuronide excretion may have important implications with respect to pharmacological and/or adverse effects (8) . For example, the side effect diarrhea (a gastrointestinal toxicity) was ameliorated by decreasing the intestinal excretion of SN-38-glucuronide (13) .
The BCRP-glucuronide interaction complicates the efforts to predict glucuronidation, and gives rise to the "UGT-BCRP interplay" phenomenon (14, 15) . Understanding the transport kinetics is of important value in predicting the contribution of BCRP to drug/glucuronide disposition in vivo, and/or in determining the rate-limiting step (metabolism vs. excretion) of cellular glucuronide production. The transport kinetic parameters (i.e., K m , V max and CL int 0 V max /K m ) of efflux transporters are often obtained by the transport assay using plasma membrane (inside-out) vesicles that contains a large amount of the efflux transporter (16) . However, the requirement to use purified BCRP substrate for experimentation limits the use of this assay in evaluation of BCRP-mediated glucuronide efflux, usually because of lack of commercial availability of the glucuronides. In this study, we utilize a recently developed engineered cell (i.e., HeLa cells over-expressing UGT1A9, or HeLa1A9 cells) to kinetically determine BCRP-mediated transport of glucuronides (17) . One major advantage of our method is that it avoids the use of purified glucuronide. Validation of this method was performed theoretically (i.e., pharmacokinetic modeling and simulation) and experimentally (i.e., the transport kinetic results derived from HeLa1A9 cells were correlated to those from BCRP membrane vesicles).
MATERIALS AND METHODS

Materials
Human BCRP (Arg482) membrane vesicles and expressed UGT1A9 (Supersomes™) were purchased from BD Biosciences (Woburn, MA). 4-Methylumbelliferone (4MU), 4-methylumbelliferone-glucuronide (4MU-G), Leukotriene C4 (LTC4), Ko143, uridine diphosphoglucuronic acid (UDPGA), alamethicin, D-saccharic-1,4-lactone monohydrate, magnesium chloride, and Hanks' balanced salt solution (HBSS, powder form) were purchased from Sigma-Aldrich (St Louis, MO). Ammonium acetate and Tris-HCl were purchased from J.T. Baker (Phillipsburg, NT). 6-Hydroxylfavone (6HF) was purchased from Indofine Chemicals (Somerville, NJ). 6-Hydroxyflavone glucuronide (6HF-G)) was synthesized as described previously (18, 19) . GF/F glass fiber filters were obtained from Whatman (Piscataway, NJ). All other materials (typically analytical grade or better) were used as received.
Cell Culture
UGT1A9 transfected HeLa cells (referred to as HeLa1A9 cells in this paper) were seeded into Transwells™ at a density of 100,000 cells/well, and were grown using Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. Cells from 2 to 3 days past seeding were used for the experiments. Detailed molecular characterizations on HeLa1A9 cells were performed previously and published (17) . Direct determination of HeLa1A9 cell volume is not reported. Nevertheless, for Caco-2 cells, the cell volume was estimated to be 3.66 μl/mg protein (20) by geometrical estimation, and 4.05 μl/mg protein (21) by the cellular accumulation study of sulfanilamide. By analogy, in this study, the HeLa1A9 cell volume was assigned as the average of those two determinations, or 3.86 μl/mg protein (22, 23) . Based on 3.86 μl/mg protein and 0.99 mg protein/Transwell™, the cell volume for the HeLa1A9 cells grown on a Transwell™ (surface area 4.2 cm 2 ) is estimated to be 3.82 μl.
Preparation of HeLa Cell Lysate
Membranes of HeLa1A9 cells (from 75 ml flask) cultured for 3 days were disrupted in pH 7.4 HBSS buffer, by sonication for 15 min in an ice-cold water bath. The protein content of the lysate was determined by the Bio-Rad protein assay kit (Bio-Rad, Hercules, CA), using bovine serum albumin as the standard.
Protein Binding of 6HF, 4MU and Their Glucuronides with HeLa Lysate
The extent of binding of parent compounds and glucuronides (1.6-50 μM) to HeLa1A9 cell lysate was investigated, as described previously (23) . The solute was incubated with cell lysate (final lysate protein concentration 0.54 mg/ml) at 37°C for 15 min, and the mixture was rapidly filtered through a filter membrane (3000 mol. wt. cut-off; Millipore Corporation, Billerica, MA) by centrifugation at 15,000 g for 15 min. The control experiment was carried out with the compound present in HBSS buffer, pH 7.4. The filtrate was assayed for protein by Bio-Rad protein assay kit to check for leakiness. Protein binding was calculated according to %unbound0C u /C×100%, where C u is the concentration of the compound in the ultrafiltrate, and C is the concentration of the compound obtained from the filtrate in the control experiment. The samples were analyzed by UPLC.
Glucuronide Excretion Experiments in the HeLa1A9 Cell Model
All culture wells were washed three times with 37°C HBSS (pH 7.4) prior to experimentation. HeLa1A9 cells were incubated in HBSS (2 ml) containing different concentrations of the parent compound (aglycone). The concentrations of the parent compound and the glucuronide in incubation medium were measured by UPLC. Inhibitors, when used, were co-incubated with the aglycone. At each specified time points (i.e., 30, 60, 90, and 120 min, unless otherwise specified), 200 μl samples were taken and then replaced with the same volume of dosing solution (containing the parent compound). After the last time point, the medium was rapidly removed by suction and the cells were washed at least twice with ice-cold HBSS. Intracellular measurements of parent drugs and metabolites were obtained by solubilizing each cell culture well with 500 μl of ice-cold MeOH:H 2 O (7:3, v/v) and sonicating the mixture (in an ice-cold ultrasonic bath) for 15 min. The homogenate was centrifuged for 15 min at 15,000 g, and the resulting supernatant was analyzed by UPLC. Glucuronide excretion rate was determined from the excretion rate vs. time profile using linear regression (rate equals to the slope).
Glucuronidation Assay
As described previously (24) (25) (26) , the aglycones (6HF and 4MU) were incubated with expressed UGT1A9 or HeLa1A9 cell lysate. All experiments were performed in triplicates. The incubation medium consisted of 50 mM potassium phosphate buffer (pH 07.4) with 0.88 mM MgCl 2 , 4.4 mM saccharolactone, 22 μg/ml alamethicin, and 3.5 mM UDPGA (add last). The reaction was terminated by the addition of 50 μl of 94% acetonitrile/6% glacial acetic acid, followed by centrifugation at 15,000 rpm for 15 min. The resultant supernatant was directly subjected to UPLC analysis. Glucuronide(s) formation was verified to be linear with respect to incubation time (30-180 min) and protein concentration (13-53 μg/ml). Glucuronidation rates were calculated as nmol glucuronide(s) formed per reaction time per protein amount (or nmol/min/mg protein).
Pharmacokinetictic Modeling and Simulation
A two-compartment model, consisting of the (incubation) medium and the cell compartments, was used to describe the transport and glucuronidation in HeLa1A9 cells (Fig. 1a, b) . The mass balance equations were shown (eqs. 1-4). Transport of the aglycone (A) across the cell membrane occurs with the rate constants K in and K out , representing the summation of passive diffusion and active transport. Glucuronide (G) formation and excretion follow Michaelis-Menten (saturable) kinetics described by V max and K m , and J max and K' m , respectively. f a and f g denote the unbound fractions of aglycone and conjugate in the cell compartment, respectively. The model assumes (1) glucuronidation is the only metabolic pathway; (2) there is no conversion of glucuronide back to the aglycone (deglucurondation); (3) transport of aglycone across the membrane is a non-saturable (linear) process. All simulations were performed using MATLAB® (The Mathsworks Inc, Natick, MA). The glucuronide excretion data at the 30, 60, 90, or 120 min were used to calculate the excretion rates. In all simulations, the protein binding of glucuronide was assumed to be unity (f g 01).
Kinetics Analysis
Kinetic parameters (V max and K m for glucuronide formation; J max and K' m for glucuronide excretion) were estimated by fitting Michaelis-Menten equation to the data by nonlinear least-squares regression using a weighting of 1/y. Data analysis was performed by GraphPad Prism V5 for Windows (GraphPad Software, San Diego, CA). The goodness of fit was evaluated on the basis of R 2 values, RSS (residual sum of squares), RMS (root mean square) and residual plots.
Vesicular Transport Studies for BCRP
Vesicular transport studies were performed with rapid filtration techniques as described previously (27) (28) (29) . In brief, membrane fractions containing inside out efflux transporters were incubated in the presence or absence of 5 mM ATP in a buffer containing 10 mM MgCl 2 and 10 mM Tris/HCl (pH 7.4). The transport was stopped by addition of 1 ml of cold transport buffer to the membrane suspensions and then rapidly filtered through class F glass fiber filters (pore size, 0.45 μm). Filters were washed with 2× 5 ml of ice-cold wash buffer, cut and transferred to a 1.5-ml Eppendorf tube containing 400 μl of 50% methanol, followed by sonicating for 15 min. After centrifugation at 15,000 rpm for 15 min, the supernatant was subjected into UPLC quantitative analysis. ATP-dependent transport was calculated by subtracting the values obtained in the presence of AMP from those in the presence of ATP.
UPLC Analysis
The Waters ACQUITY™ UPLC (Ultra performance liquid chromatography) system was used to analyze the parent compounds and their respective glucuronides. The UPLC condition was described in our earlier publications (24) (25) (26) .
Statistical Analysis
One-way ANOVA with or without Tukey-Kramer multiple comparison (post hoc) tests was used to evaluate statistical differences. Differences were considered significant when p values were less than 0.05 (p<0.05).
RESULTS AND DISCUSSION
Theoretical Validation of HeLa1A9 Cells to Determine Kinetic Parameters for BCRP with Glucuronides
Glucuronide formation and excretion in HeLa1A9 cells were simulated based on a two-compartment pharmacokinetic model (Fig. 1a, b) and varied model parameters (Table I) . Interestingly, a steady-state (i.e., zeroorder or near zero-order) excretion for glucuronide is observed (Fig. 1c) . When the aglycone dose (for incubation) is increased, both excretion rate and the intracellular concentration (for glucuronide) also increased ( Fig. 1c, d ). The kinetic parameters were derived by plotting the excretion rates vs. the glucuronide concentrations (Fig. 1e) . Using this approach, we have estimated the kinetic constants (K' m and J max ) based on simulation data and compared them with the assigned (true) values (Table I ). The estimates are close or identical to the true values, suggesting that our model may be used for determining the kinetics of BCRP-mediated glucuronide transport.
Experimental Validation of HeLa1A9 Cells to Determine Kinetic Parameters for BCRP with Glucuronides
In this paper, we mainly used 6-hydroxyflavone (6HF) and 4-methylumbelliferone (4MU) and their glucuronides (see Binding of 6HF to HeLa1A9 cell lysate protein was extensive, whereas binding of 4MU was modest (Fig. 2b,  c) . The unbound fractions of 6HF and 4MU (1.6-50 μM) were <0.02% and 40%-57%, respectively. By contrast, as expected, binding of the polar glucuronides to HeLa1A9 *Based on simulation data using the two-compartment model (Fig. 1b) .
cell lysate protein was negligible (Fig. 2b, c) . The unbound fractions of 6HF-G and 4MU-G (1.6-50 μM) were 95%-104% and 96%-99%, respectively. UGTs present in HeLa1A9 cell lysate glucuronidated 6HF and 4MU with K m values similar (p>0.05) to those derived using recombinant UGT1A9 (2.9 vs. 2.3 μM for 6HF; 10 vs. 12 μM for 4MU) (Fig. 2d, e) . However, compared to recombinant UGT1A9, HeLa1A9 cell lysate exhibited much smaller V max values (3.5 vs. 76 pmol/min/mg for 6HF; 52 vs. 3653 pmol/min/mg for 4MU) (Fig. 2d, e) , suggesting that HeLa1A9 cell lysate had a much lower UGT1A9 expression. Although 6HF and 4MU were significantly bound to HeLa1A9 cell lysate (Fig. 2b, c) , the K m values were not corrected for protein binding. This is because the nonspecific binding of 6HF and 4MU estimated using the HallifaxHouston model (30) under the incubation conditions (26.5 μg/ml protein) was less than 5%. Similar to an earlier study (31) , the logP values (6HF, 3.12; 4MU, 1.95) used for the protein binding estimation were calculated with the Molinspiration property calculator (http://www.molinspiration.com/ services/logp.html).
The key role of BCRP in excretion of glucuronide was determined by inhibition studies. When LTC4 (a specific inhibitor of multidrug resistance proteins (MRPs), 0.1-0.4 μM) was applied, glucuronidation in HeLa1A9 cells was not affected at all, since no changes were observed in the amounts of excreted glucuronide or the intracellular glucuronide or intracellular aglycones (Fig. 3a, c) . By contrast, inhibition of BCRP by a specific inhibitor Ko143 (5-20 μM) (32) resulted in significantly reduced glucuronide excretion but elevated accumulation of intracellular glucuronide (Fig. 3b,  c) . The inhibitory effect on excretion rate was dosedependent (p<0.05), and the extent of decreases were 11%, 16%, and 32% at 5, 10 and 20 μM Ko143, respectively. At the same time, the intracellular concentrations of glucuronide were increased by 2.9-, 4.3-, and 9.8-fold at 5, 10 and 20 μM Ko143, respectively. As a result, the apparent glucuronide clearance (CL app 0excretion rate/intracellular level) was decreased by 2.7-, 4.1-, 12.6-fold at 5, 10 and 20 μM Ko143, respectively (Fig. 3d) . It was suggested that deglucuronidation (or β-glucuronidase) activity is none or minimal, since total amount of formed glucuronide (i.e., sum of excreted and accumulated glucuronide) was not altered (p>0.05) by efflux inhibition. The data consistently indicated that BCRP not MRPs was responsible for the glucuronide excretion in HeLa1A9 cells. The main role of BCRP in excretion of glucuronide in HeLa1A9 cell model was also confirmed by inhibition studies using 4MU (data not shown) and other compounds, as well as molecular characterization on potential efflux transporters (17) . Of note, the expression of MRP2 and MRP3, two potential glucuronide transporters, were not detected (17) . Some aglycones such as flavonoids were reported to be either BCRP inhibitors or substrates (33, 34) . To rule out the possibility that the aglycone itself might interfere with the glucuronide-BCRP interaction, we confirmed that SN-38 (a BCRP substrate) or biochanin A (a potential inhibitor) (16, 33) , dosed at 10 μM did not affect the glucuronidation of 6HF (1-50 μM) in HeLa1A9 cell model (data not shown). On the other hand, the excretion of glucuronide in HeLa1A9 cells follows a zero-order kinetic pattern even at high substrate concentrations, which suggests that inhibition of this process is none or minimal. Significant inhibition of glucuronide efflux, if any, would have resulted in an excretion-time profile with a notable time lag as observed in Fig. 3b . Therefore, the impact of tested aglycone itself (≤10 μM) on the excretion of its glucuronide via BCRP inhibition should be negligible in HeLa1A9 cells under the current experimental conditions.
The excretion of 6HF-G followed a (near) zero-order kinetic pattern under various 6HF concentrations (0.5-50 μM) (Fig. 4a) . By varying the loading concentration, intracellular concentration (at the end of experiment or 120 min) of 6HF-G was altered accordingly (Fig. 4b) . Therefore, the integration of the different (intracellular) 6HF-G concentrations with their corresponding excretion rates enabled us to derive the transport kinetic parameters. The obtained K m value for BCRPmediated transport of 6HF-G was comparable (p>0.05) to that from BCRP membrane vesicles (15 vs . 23 μM, Fig. 4c) . However, the V max values differed by 6.6 -fold, probably due to the differences in BCRP expression level. The same approach was applied to determine the kinetic parameters for BCRP-mediated transport of 4MU-G (Fig. 4d-f) . The obtained K m value was very close (p>0.05) to that from BCRP membrane vesicles (24 vs. 27 μM, Fig. 4f ), whereas V max value was 6.6-fold lower than that determined using BCRP membrane vesicles as observed for 6HF-G.
It is noteworthy that the use of HeLa1A9 cell model to study BCRP-glucuronide interaction is limited to those glucuronides whose precursors (aglycones) are at least fare substrates of UGT1A9. No glucuronide excretion was observed when incubating very poor UGT1A9 substrates such as estradiol and ezetimibe with HeLa1A9 cells, thus precluding evaluation of BCRP interaction with their glucuronides. In addition, the aglycone should be permeable to gain access to inside of the cells. A logP value of 1.856 .46 might be necessary based on a screening of 27 structurally diverse aglycones dosed at a concentration of 10 μM (data not shown). Studies are ongoing to derive the activity of BCRP towards structurally diverse glucuronides and to establish the quantitative structure-activity relationships.
CONCLUSION
Understanding of BCRP-glucuronide interaction and the kinetics should facilitate predictions of BCRP-mediated glucuronide clearance in vivo. In this paper, we propose a new strategy to determine the kinetic parameters of BCRPmediated glucuronide efflux using the HeLa1A9 cells. The proposed strategy is based on the measurement of intracellular glucuronide concentrations and the corresponding excretion rates of glucuronides after loading different concentrations of the parent compounds on the HeLa1A9 cells. The results indicated that the use of new HeLa1A9 cell model represents a viable new strategy to rapidly evaluate the kinetics of interaction between glucuronides and efflux transporters.
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